<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701099</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0182</org_study_id>
    <nct_id>NCT04701099</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Vancomycin, Meropenem, Milrinone, Dexmedetomidine and Fentanyl in Pediatric Patients During Extracorporeal Membrane Oxygenation</brief_title>
  <official_title>Population Pharmacokinetics of Vancomycin, Meropenem, Milrinone, Dexmedetomidine and Fentanyl in Pediatric Patients During Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) has been used primarily in newborns since it was&#xD;
      first successfully implemented in the 1970s, and has recently increased use in infants and&#xD;
      young children. Venoarterial ECMO (VA-ECMO) is a temporary mechanical circulatory support for&#xD;
      patients with cardiac failure. Because ECMO is invasive, appropriate use of antimicrobial&#xD;
      agent, analgesic and sedatives is important to promote recovery. However, a large variability&#xD;
      in drugs pharmacokinetics is expected in pediatric ECMO patients due to the combination of&#xD;
      ECMO, drug characteristics and disease factor. This study aimed to evaluate whether the PK of&#xD;
      drugs is influenced by VA-ECMO and to recommend the optimal dosing strategies for proposed&#xD;
      drugs in pediatric patients receiving VA-ECMO.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum or plasma concentration</measure>
    <time_frame>Between day0 to day3 during ECMO</time_frame>
    <description>Serum or plasma concentration of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum or plasma concentration</measure>
    <time_frame>Between day0 to day3 after weaning off ECMO</time_frame>
    <description>Serum or plasma concentration of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Volume of distribution</measure>
    <time_frame>Between day0 to day3 during ECMO</time_frame>
    <description>Volume of distribution of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Volume of distribution</measure>
    <time_frame>Between day0 to day3 after weaning off ECMO</time_frame>
    <description>Volume of distribution of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Clearance</measure>
    <time_frame>Between day0 to day3 during ECMO</time_frame>
    <description>Clearance of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Clearance</measure>
    <time_frame>Between day0 to day3 after weaning off ECMO</time_frame>
    <description>Clearance of vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pediatric Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation</condition>
  <arm_group>
    <arm_group_label>On ECMO</arm_group_label>
    <description>patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off ECMO</arm_group_label>
    <description>patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At each sampling time, an arterial blood sample (1 to 2 mL) is collected from all subjects&#xD;
      during ECMO support and after weaning off ECMO for drug concentration assay (LC-MS/MS, etc.).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under the age of 19 who are receiving vancomycin or meropenem or milrinone or&#xD;
        dexmedetomidine or fentanyl while using VA ECMO in Severance Hospital, Yonsei University&#xD;
        Health System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &lt;19 years old&#xD;
&#xD;
          -  receiving VA ECMO in Severance Hospital, Yonsei University Health System.&#xD;
&#xD;
          -  receiving one of these drugs: vancomycin or meropenem or milrinone or dexmedetomidine&#xD;
             or fentanyl&#xD;
&#xD;
          -  agreed to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  receiving drugs that could affect study drug's concentration due to drug-drug&#xD;
             interaction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Rim Shin, Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Rim Shin, Assistant Professor</last_name>
    <phone>82-2-2228-8480</phone>
    <email>yull0629@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Thoracic and Cardiovascular Surgery, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Rim Shin, Assistant Professor</last_name>
      <phone>82-2-2228-8480</phone>
      <email>yull0629@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

